Amazfit Launches Cheetah 2 Pro Sports Watch at $449.99
Amazfit announced the Cheetah 2 Pro, the newest addition to its performance-focused Cheetah lineup. Built for marathon runners who believe preparation is everything, the Cheetah 2 Pro is designed around a simple belief: marathon performance is shaped by the work runners do throughout the training week. It brings structured running, strength-supportive training, and recovery insights into one focused preparation system, helping runners stay consistent through long marathon build-ups. Launching ahead of the Boston and London Marathons, the Cheetah 2 Pro is built to meet the demands of high-mileage training and race day alike. The Cheetah 2 Pro will be available for purchase starting April 16, 2026, for $449.99 on Amazfit.com and select retailers.
Trade with 70% Backtested Accuracy
Analyst Views on ZEPP

No data
About ZEPP
About the author

- Multi-Sensor System: The Helio Strap Pro combines upper-arm heart rate monitoring with a waist-mounted motion sensor to provide a comprehensive analysis of performance, enabling HYROX and hybrid athletes to better understand their body's response under fatigue, thereby enhancing training effectiveness.
- Integration of Training and Recovery: This system not only supports real-time monitoring of training data but also integrates workouts, recovery, and daily habits into a continuous view of progress through the Zepp App, helping athletes optimize their training plans and recovery strategies.
- Compatibility and Connectivity: Helio Strap Pro supports Bluetooth connectivity with various Amazfit smartwatches and third-party devices, allowing real-time sharing of heart rate data, which enhances athletes' flexibility and adaptability in different training environments, thus improving the overall training experience.
- Market Positioning and Pricing: Scheduled for release at the end of June 2026, priced at $199.99, Helio Strap Pro aims to attract athletes interested in hybrid training through its innovative monitoring features, further solidifying Amazfit's leadership position in the smart wearable market.
- Financial Performance: Zepp Health reported a net loss of $19.64 million in Q1 2026, translating to a loss of $0.08 per share, which is an improvement from the $19.74 million loss in 2025, indicating better gross profit due to higher revenues.
- Revenue Growth: The company achieved revenues of $51.55 million in the first quarter, a 33.5% increase from $38.54 million a year ago, reflecting significant progress in market demand despite ongoing losses.
- Product Launches: In Q1, Zepp introduced several new products, including the Amazfit Balance 3 and Amazfit Cheetah 2 Ultra, which are designed to help users monitor health parameters during physical activities, thereby enhancing its competitive position in the wearable tech market.
- Future Outlook: The company estimates Q2 revenues to range between $63 million and $68 million, representing a 6% to 14% increase from $59.4 million reported in Q2 2025, indicating an optimistic outlook for future performance despite a 28% drop in stock price post-announcement.
- Significant Revenue Growth: Zepp Health reported Q1 revenue of $51.5 million, a 33.8% year-over-year increase, showcasing strong market performance in a traditionally slow quarter, which is expected to further enhance the brand's share in the smart wearable market.
- Slight Margin Improvement: The gross margin stood at 37.7%, up 0.4% year-over-year, despite pressures from higher memory component costs and unfavorable foreign exchange fluctuations, indicating the company's ability to maintain some cost control.
- Narrowed Operating Loss: Operating loss decreased from $17.2 million in the previous year to $6.3 million, reflecting progress in cost management and operational efficiency, with potential for future profitability growth.
- Optimistic Future Outlook: The company expects Q2 revenue to range between $63 million and $68 million, representing a year-over-year growth of approximately 6% to 14%, driven by new product launches and strong market demand, further solidifying its market position.
- Revenue Growth: Zepp Health reported a 33.8% year-over-year revenue increase to $51.5 million in Q1, aligning with guidance and driven by new product launches, although overall market sentiment was weighed down by ongoing losses.
- Margin Fluctuations: Gross margin edged up to 37.7% from 37.3% a year earlier, but declined sequentially due to lower-margin product refreshes, higher component costs, and currency headwinds, indicating challenges in cost management.
- Net Loss Report: The company reported a net loss of $19.6 million, roughly unchanged from the previous year, while the adjusted operating loss narrowed to $16.3 million, suggesting some progress in operational efficiency improvements.
- Future Outlook: Zepp expects second-quarter revenue between $63 million and $68 million, implying a year-over-year growth of 6% to 14%, reflecting the company's optimistic outlook on market demand.
- Earnings Highlights: Zepp Health reported a Q1 2026 non-GAAP EPS of -$1.13, yet achieved revenues of $51.55 million, reflecting a robust year-over-year growth of 33.8%, indicating strong market demand.
- Gross Margin Improvement: The gross margin for Q1 stood at 37.7%, an increase of 0.4 percentage points compared to Q1 2025, showcasing effective cost management and operational efficiency that enhance profitability.
- Future Outlook: Management anticipates Q2 2026 net revenues between $63.0 million and $68.0 million, representing a year-over-year growth of approximately 6% to 14%, which underscores confidence in sustained market demand.
- Risk Assessment: Despite significant revenue growth, analysts have downgraded Zepp Health's rating, citing concerns over compressing gross margins, which may pose challenges to future profitability and investor sentiment.









